Cohort Study of the Clinical Course of Macular Diseases in Japanese

Kyoto University, Graduate School of Medicine

Status: Unknown

Conditions: Macular Disease

Treatments: Drug: ranibizumab, aflibercept, pegaptanib, verteporphin

Study type: Observational

Funder types: Other

Identifiers

NCT02081339

E2038

Details and patient eligibility

About

Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth.

Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

Enrollment: 1,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who visit Department of Ophthalmology Kyoto University Hospital with macular diseases.
• Patients who are agreed with the participation of this study.

Exclusion criteria

• None

Trial design

1,000 participants in 1 patient group

Macular diseases

Description:

ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡

Treatment:

Drug: ranibizumab, aflibercept, pegaptanib, verteporphin